Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Extracellular matrix powder protects against bleomycin-induced pulmonary fibrosis.

Manni ML, Czajka CA, Oury TD, Gilbert TW.

Tissue Eng Part A. 2011 Nov;17(21-22):2795-804. doi: 10.1089/ten.tea.2011.0023. Epub 2011 Jul 28.

2.

Inhibition of pulmonary fibrosis by the chemokine IP-10/CXCL10.

Tager AM, Kradin RL, LaCamera P, Bercury SD, Campanella GS, Leary CP, Polosukhin V, Zhao LH, Sakamoto H, Blackwell TS, Luster AD.

Am J Respir Cell Mol Biol. 2004 Oct;31(4):395-404. Epub 2004 Jun 17.

PMID:
15205180
3.

Megakaryoblastic leukemia-1 is required for the development of bleomycin-induced pulmonary fibrosis.

Bernau K, Ngam C, Torr EE, Acton B, Kach J, Dulin NO, Sandbo N.

Respir Res. 2015 Mar 27;16:45. doi: 10.1186/s12931-015-0206-6.

4.

The transcription factor NRF2 protects against pulmonary fibrosis.

Cho HY, Reddy SP, Yamamoto M, Kleeberger SR.

FASEB J. 2004 Aug;18(11):1258-60. Epub 2004 Jun 18.

PMID:
15208274
5.

VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.

Ou XM, Li WC, Liu DS, Li YP, Wen FQ, Feng YL, Zhang SF, Huang XY, Wang T, Wang K, Wang X, Chen L.

Int Immunopharmacol. 2009 Jan;9(1):70-9. doi: 10.1016/j.intimp.2008.10.002. Epub 2008 Oct 29.

PMID:
18976720
6.

HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis.

Mizuno S, Matsumoto K, Li MY, Nakamura T.

FASEB J. 2005 Apr;19(6):580-2. Epub 2005 Jan 21.

PMID:
15665032
7.

Prostaglandin E₂ protects murine lungs from bleomycin-induced pulmonary fibrosis and lung dysfunction.

Dackor RT, Cheng J, Voltz JW, Card JW, Ferguson CD, Garrett RC, Bradbury JA, DeGraff LM, Lih FB, Tomer KB, Flake GP, Travlos GS, Ramsey RW Jr, Edin ML, Morgan DL, Zeldin DC.

Am J Physiol Lung Cell Mol Physiol. 2011 Nov;301(5):L645-55. doi: 10.1152/ajplung.00176.2011. Epub 2011 Aug 19.

8.

Role of the chemokine receptor CXCR2 in bleomycin-induced pulmonary inflammation and fibrosis.

Russo RC, Guabiraba R, Garcia CC, Barcelos LS, Roffê E, Souza AL, Amaral FA, Cisalpino D, Cassali GD, Doni A, Bertini R, Teixeira MM.

Am J Respir Cell Mol Biol. 2009 Apr;40(4):410-21. doi: 10.1165/rcmb.2007-0364OC. Epub 2008 Oct 3.

PMID:
18836137
9.

Azithromycin reduces pulmonary fibrosis in a bleomycin mouse model.

Wuyts WA, Willems S, Vos R, Vanaudenaerde BM, De Vleeschauwer SI, Rinaldi M, Vanhooren HM, Geudens N, Verleden SE, Demedts MG, Thomeer M, Verbeken EK, Verleden GM.

Exp Lung Res. 2010 Dec;36(10):602-14. doi: 10.3109/01902148.2010.492895. Epub 2010 Sep 27.

PMID:
20874225
10.

Inhibitory effect of emodin on bleomycin-induced pulmonary fibrosis in mice.

Chen XH, Sun RS, Hu JM, Mo ZY, Yang ZF, Jin GY, Guan WD, Zhong NS.

Clin Exp Pharmacol Physiol. 2009 Feb;36(2):146-53. doi: 10.1111/j.1440-1681.2008.05048.x. Epub 2008 Sep 10.

PMID:
18785980
11.

Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis.

Howell DC, Laurent GJ, Chambers RC.

Biochem Soc Trans. 2002 Apr;30(2):211-6. Review.

PMID:
12023853
12.

Characterization of lung stem cell niches in a mouse model of bleomycin-induced fibrosis.

Banerjee ER, Henderson WR Jr.

Stem Cell Res Ther. 2012 May 29;3(3):21. doi: 10.1186/scrt112.

13.

Role of lung apolipoprotein A-I in idiopathic pulmonary fibrosis: antiinflammatory and antifibrotic effect on experimental lung injury and fibrosis.

Kim TH, Lee YH, Kim KH, Lee SH, Cha JY, Shin EK, Jung S, Jang AS, Park SW, Uh ST, Kim YH, Park JS, Sin HG, Youm W, Koh ES, Cho SY, Paik YK, Rhim TY, Park CS.

Am J Respir Crit Care Med. 2010 Sep 1;182(5):633-42. doi: 10.1164/rccm.200905-0659OC. Epub 2010 May 12.

PMID:
20463180
14.

Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects.

Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG.

Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8407-11. Epub 2003 Jun 18.

15.

The role of the receptor for advanced glycation end-products in lung fibrosis.

He M, Kubo H, Ishizawa K, Hegab AE, Yamamoto Y, Yamamoto H, Yamaya M.

Am J Physiol Lung Cell Mol Physiol. 2007 Dec;293(6):L1427-36. Epub 2007 Oct 19.

16.

Rac2 is involved in bleomycin-induced lung inflammation leading to pulmonary fibrosis.

Arizmendi N, Puttagunta L, Chung KL, Davidson C, Rey-Parra J, Chao DV, Thebaud B, Lacy P, Vliagoftis H.

Respir Res. 2014 Jun 27;15:71. doi: 10.1186/1465-9921-15-71.

17.

Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis.

Senoo T, Hattori N, Tanimoto T, Furonaka M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Yokoyama A, Kohno N.

Thorax. 2010 Apr;65(4):334-40. doi: 10.1136/thx.2009.119974.

PMID:
20388759
18.

Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.

Suzuki H, Aoshiba K, Yokohori N, Nagai A.

Cancer Res. 2003 Aug 15;63(16):5054-9.

19.

Exacerbation of bleomycin-induced injury and fibrosis by pneumonectomy in the residual lung of mice.

Kakizaki T, Kohno M, Watanabe M, Tajima A, Izumi Y, Miyasho T, Tasaka S, Fukunaga K, Maruyama I, Ishizaka A, Kobayashi K.

J Surg Res. 2009 Jun 15;154(2):336-44. doi: 10.1016/j.jss.2008.06.021. Epub 2008 Jul 15.

PMID:
19118846
20.

Epithelial cell-derived transforming growth factor-beta in bleomycin-induced pulmonary injury.

Kumar RK, O'Grady R, Maronese SE, Wilson MR.

Int J Exp Pathol. 1996 Jun;77(3):99-107.

Supplemental Content

Support Center